Spire Wealth Management
ARCT icon

Spire Wealth Management’s Arcturus Therapeutics ARCT Stock Holding History

Spire Wealth Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,955
Closed -$130K – 2363
2025
Q2 		$130K Buy
9,955
+4,300
+76% +$50.8K ﹤0.01% 881
2025
Q1 		$59.9K Sell
5,655
-7,823
-58% -$124K ﹤0.01% 1221
2024
Q4 		$229K Buy
13,478
+10,746
+393% +$202K 0.01% 783
2024
Q3 		$63.4K Buy
+2,732
New +$58.4K ﹤0.01% 1064
2023
Q4 		– Sell
-310
Closed -$7.92K – 2363
2023
Q3 		$7.92K Buy
+310
New +$9.55K ﹤0.01% 1800

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Spire Wealth Management's ARCT Position: Q3 2025 in Review

Spire Wealth Management sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 9,955 shares — an estimated $130K sold.

Spire Wealth Management first reported a position in ARCT in Q3 2023 and held it in 5 quarters. The position peaked at $229K in Q4 2024. 137 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Spire Wealth Management reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Spire Wealth Management sold 9,955 Arcturus Therapeutics shares in Q3 2025, an estimated $130K.
  • Spire Wealth Management first reported a position in Arcturus Therapeutics in Q3 2023 and held it in 5 quarters.
  • Spire Wealth Management's Arcturus Therapeutics position peaked at $229K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Spire Wealth Management's 13F filing for Q3 2025, filed 23 Oct 2025.